Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(5.41%)
AUD 0.2
(5.41%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -6.2 Million AUD | 61.62% |
| 2023 | -16.16 Million AUD | 32.06% |
| 2022 | -23.79 Million AUD | 10.92% |
| 2021 | -26.71 Million AUD | -95.73% |
| 2020 | -13.64 Million AUD | -95.63% |
| 2019 | -6.97 Million AUD | 42.84% |
| 2018 | -12.2 Million AUD | -17.94% |
| 2017 | -10.34 Million AUD | -112.12% |
| 2016 | -4.87 Million AUD | -4.46% |
| 2015 | -4.67 Million AUD | 8.31% |
| 2014 | -5.09 Million AUD | -356.26% |
| 2013 | -1.11 Million AUD | -12.44% |
| 2012 | -993.07 Thousand AUD | -168.96% |
| 2011 | -369.23 Thousand AUD | 41.17% |
| 2010 | -627.61 Thousand AUD | 37.55% |
| 2009 | -1 Million AUD | 51.67% |
| 2008 | -2.07 Million AUD | 35.98% |
| 2007 | -3.24 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.16 Million AUD | 0.0% |
| 2024 Q4 | -6.2 Million AUD | 0.0% |
| 2024 FY | -6.2 Million AUD | 61.62% |
| 2023 FY | -16.16 Million AUD | 32.06% |
| 2023 Q4 | -16.16 Million AUD | 0.0% |
| 2023 Q2 | -16.41 Million AUD | 0.0% |
| 2022 Q2 | -26.78 Million AUD | 0.0% |
| 2022 FY | -23.79 Million AUD | 10.92% |
| 2022 Q4 | -23.79 Million AUD | 0.0% |
| 2021 Q2 | -24.91 Million AUD | 0.0% |
| 2021 Q4 | -26.71 Million AUD | 0.0% |
| 2021 FY | -26.71 Million AUD | -95.73% |
| 2020 Q4 | -13.64 Million AUD | 0.0% |
| 2020 FY | -13.64 Million AUD | -95.63% |
| 2020 Q2 | -5.91 Million AUD | 0.0% |
| 2019 Q2 | -10.63 Million AUD | 0.0% |
| 2019 FY | -6.97 Million AUD | 42.84% |
| 2019 Q4 | -6.97 Million AUD | 0.0% |
| 2018 FY | -12.2 Million AUD | -17.94% |
| 2018 Q2 | -8.83 Million AUD | 0.0% |
| 2018 Q4 | -12.2 Million AUD | 0.0% |
| 2017 Q2 | -3.91 Million AUD | 0.0% |
| 2017 Q4 | -10.34 Million AUD | 0.0% |
| 2017 FY | -10.34 Million AUD | -112.12% |
| 2016 Q2 | -6.36 Million AUD | 0.0% |
| 2016 Q4 | -4.87 Million AUD | 0.0% |
| 2016 FY | -4.87 Million AUD | -4.46% |
| 2015 Q2 | -6.15 Million AUD | 0.0% |
| 2015 Q4 | -4.67 Million AUD | 0.0% |
| 2015 FY | -4.67 Million AUD | 8.31% |
| 2014 FY | -5.09 Million AUD | -356.26% |
| 2014 Q2 | -6.2 Million AUD | 0.0% |
| 2014 Q4 | -5.09 Million AUD | 0.0% |
| 2013 Q2 | -1.47 Million AUD | 0.0% |
| 2013 FY | -1.11 Million AUD | -12.44% |
| 2013 Q4 | -1.11 Million AUD | 0.0% |
| 2013 Q3 | -1.11 Million AUD | 24.16% |
| 2013 Q1 | -1.47 Million AUD | -48.26% |
| 2012 FY | -993.07 Thousand AUD | -168.96% |
| 2012 Q4 | -993.07 Thousand AUD | 0.0% |
| 2011 Q4 | -369.23 Thousand AUD | 0.0% |
| 2011 FY | -369.23 Thousand AUD | 41.17% |
| 2010 FY | -627.61 Thousand AUD | 37.55% |
| 2010 Q4 | -627.61 Thousand AUD | 0.0% |
| 2009 FY | -1 Million AUD | 51.67% |
| 2009 Q4 | -1 Million AUD | 0.0% |
| 2008 Q4 | -2.07 Million AUD | 0.0% |
| 2008 FY | -2.07 Million AUD | 35.98% |
| 2007 FY | -3.24 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -634.219% |
| Acrux Limited | -1.45 Million AUD | -325.612% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 92.176% |
| BTC Health Limited | -2.02 Million AUD | -206.872% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -103.256% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 95.454% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 96.609% |
| Biome Australia Limited | -1.56 Million AUD | -297.069% |
| Hexima Limited | -2.22 Million AUD | -178.743% |
| Immutep Limited | -122.18 Million AUD | 94.921% |
| Memphasys Limited | 4.13 Million AUD | 250.057% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 63.698% |
| Noxopharm Limited | -2.31 Million AUD | -167.483% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 38.939% |
| Race Oncology Limited | -17.18 Million AUD | 63.899% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 66.593% |
| Starpharma Holdings Limited | -19.83 Million AUD | 68.71% |
| Tissue Repair Ltd | -16.44 Million AUD | 62.257% |
| Biotron Limited | -386.06 Thousand AUD | -1507.338% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 50.276% |
| CSL Limited | 15.76 Billion AUD | 100.039% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 67.165% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -531.847% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -774.547% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 222.459% |
| Patrys Limited | -2.24 Million AUD | -176.946% |
| Orthocell Limited | -19.92 Million AUD | 68.856% |
| Imugene Limited | -91.56 Million AUD | 93.223% |
| PYC Therapeutics Limited | -65.76 Million AUD | 90.564% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 1.873% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 51.194% |
| Nanollose Limited | -96.22 Thousand AUD | -6348.863% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -2.993% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -25.257% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -240.286% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -401.08% |
| Nyrada Inc. | -4.76 Million AUD | -30.11% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 94.134% |
| Dimerix Limited | -21.99 Million AUD | 71.783% |
| PharmAust Limited | -9.71 Million AUD | 36.12% |
| AnteoTech Limited | -5 Million AUD | -24.071% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 64.705% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -82.72% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -16.441% |
| Actinogen Medical Limited | -9.13 Million AUD | 32.045% |
| Immuron Limited | -11.48 Million AUD | 45.964% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 61.003% |